BioCentury
ARTICLE | Clinical News

Aviscumine: Phase II data

July 18, 2011 7:00 AM UTC

An open-label, German Phase II trial in 31 patients with unresectable stage IV metastatic melanoma who failed prior anti-neoplastic therapy showed that twice-weekly 350 ng subcutaneous Aviscumine led ...